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Abstract
Noonan Syndrome with Multiple Lentigines (NSML, formerly LEOPARD syndrome) is an
autosomal dominant "RASopathy" disorder manifesting in congenital heart disease. Most
cases of NSML are caused by catalytically inactivating mutations in the protein tyrosine
phosphatase (PTP), non-receptor type 11 (PTPN11), encoding the SH2 domain-containing
PTP-2 (SHP2) protein. We previously generated knock-in mice harboring the PTPN11
mutation Y279C, one of the most common NSML alleles; these now-termed SHP2Y279C/+
mice recapitulate the human disorder and develop hypertrophic cardiomyopathy (HCM) by
12 weeks of age. Functionally, heart and/or cardiomyocyte lysates from SHP2Y279C/+ mice
exhibit increased basal and agonist-induced AKT and mTOR activities. Here, we sought to
determine whether we could reverse the hypertrophy in SHP2Y279C/+ mice using ARQ 092,
an oral and selective allosteric AKT inhibitor currently in clinical trials for patients with PI3K/
AKT-driven tumors or Proteus syndrome. We obtained echocardiographs of SHP2Y279C/+
and wildtype (SHP2+/+) littermates, either in the presence or absence of ARQ 092 at 12, 14,
and 16 weeks of age. While SHP2Y279C/+ mice developed significant left ventricular hyper-
trophy by 12 weeks, as indicated by decreased chamber dimension and increased posterior
wall thickness, treatment of SHP2Y279C/+ mice with ARQ 092 normalized the hypertrophy in
as early as 2 weeks following treatment, with hearts comparable in size to those in wildtype
(SHP2+/+) mice. In addition, we observed an increase in fractional shortening (FS%) in
SHP2Y279C/+ mice, an effect of increased compensatory hypertrophy, which was not appar-
ent in SHP2Y279C/+ mice treated with ARQ 092, suggesting functional improvement of HCM
upon treatment with the AKT inhibitor. Finally, we found that ARQ 092 specifically inhibited
AKT activity, as well as its downstream effectors, PRAS and S6RP in NSML mice. Taken
together, these data suggest ARQ 092 may be a promising novel therapy for treatment of
hypertrophy in NSML patients.
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Introduction
Noonan Syndrome with Multiple Lentigines (NSML) (MIM151100), formerly known as
LEOPARD syndrome, belongs to a family of autosomal dominant “RASopathy” disorders that
are caused by mutations in components of the RAS/MAPK pathway [1–3]. NSML typically
presents with multiple phenotypic abnormalities, including multiple lentigines on the skin,
electrocardiographic conduction abnormalities, ocular hypertelorism, pulmonic stenosis,
abnormal genitalia, retardation of growth, and sensorineural deafness [4]. In addition, and the
most common and deleterious hallmark of this disease, is the presence of congenital heart
defects (CHDs), and in particular, hypertrophic cardiomyopathy (HCM), an abnormal thick-
ening of the heart that eventually leads to cardiac functional abnormalities and heart failure
[5–9]. NSML is almost exclusively caused by catalytically inactivating mutations in the protein
tyrosine phosphatase (PTP) non-receptor type 11 (PTPN11) gene that encodes the SH2
domain-containing PTP-2 (SHP2) protein [3,10]. We previously generated knock-in mice har-
boring the PTPN11 mutation Y279C (hereafter SHP2Y279C/+ mice), one of the most common
NSML mutant alleles in SHP2 [11]. These SHP2Y279C/+ mice recapitulate the human disorder,
with short stature, craniofacial dysmorphia, and morphologic, histologic, echocardiographic,
and molecular evidence of HCM [11,12]. Heart and/or cardiomyocyte lysates from adult
SHP2Y279C/+ mice show enhanced binding of SHP2 to IRS1, decreased SHP2 catalytic activity,
and abrogated agonist-evoked ERK/MAPK signaling [11]. SHP2Y279C/+ mice also exhibit
increased basal and agonist-induced AKT and mTOR activity [11,12]. Importantly, the inhibi-
tion of mTOR with rapamycin reverses the HCM phenotype in these mice [11]. Here, we
sought to determine whether the cardiac defects in SHP2Y279C/+ mice could be reversed by
treatment with the upstream regulator of mTOR, AKT, by using a novel AKT inhibitor (ARQ
092) currently in clinical trials for patients with PI3K/AKT-driven tumors and Proteus syn-
drome [13]. Data from our studies would suggest that inhibition of AKT may also be an effec-
tive treatment strategy for patients with NSML-associated HCM, and perhaps also in other,
more common, CHD-associated HCM diseases.
Results
ARQ 092 treatment normalized AKT/mTOR activity in NSML mice
The AKT/mTOR pathway is hyperactivated in SHP2Y279C/+ hearts [11,12]. SHP2 also plays a
significant, although complex, role in PI3K/AKT pathway regulation [14–16]. To determine
the effects of AKT inhibition specifically on SHP2Y279C/+ -associated hypertrophy, we isolated
whole hearts from 16-week old SHP2Y279C/+ and SHP2+/+ mice that were treated for 4 weeks
(starting at 12 weeks of age) with either vehicle or ARQ 092 (100mg/kg/day), which is in clini-
cal trials for patients with PI3K/AKT-driven tumors or Proteus syndrome [13]. Our experi-
mental dose herein was selected based on maximum tolerable dose (MTD) studies previously
conducted at ArQule, Inc., where 100mg/kg/day was found to be both sub-MTD and effica-
cious in a long-term study [13]. No mortality occurred in our cohort as a consequence of
treatment with the AKT inhibitor at this dose. At baseline, pAKT (S473) phosphorylation
was significantly increased in vehicle-treated SHP2Y279C/+ heart lysates [Fig 1A and 1B and
[11,12]]. However, in response to 4 weeks of oral gavage treatment with ARQ 092, we found
that pAKT (S473) activity was normalized in SHP2Y279C/+ hearts, to levels similar to those of
SHP2+/+ (Fig 1A and 1B). Interestingly, Proline-rich AKT1 substrate 1 (PRAS), a substrate
for AKT that relieves the inhibitory function on mTOR, did not have altered activity in
SHP2Y279C/+ hearts (Fig 1A and 1C); despite this, PRAS activity was significantly reduced
in response to ARQ 092 treatment in NSML hearts (Fig 1C). In contrast, pS6RP, a direct
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downstream target of mTOR, was hyperactivated in SHP2Y279C/+ hearts (Fig 1A and 1D), sug-
gesting that modulation of this pathway is significantly altered in NSML and that treatment
with ARQ 092 normalizes AKT/mTOR activity in SHP2Y279C/+ mouse hearts.
Inhibition of AKT signaling normalizes cardiac hypertrophy in NSML
mice
To determine the effects of ARQ 092 treatment on cardiac physiology and to assess its effects
in cardiac hypertrophy specifically in NSML mice, we conducted a series of histological
analyses. As previously described [11,12], H&E-stained transverse sections of 16-week-old
SHP2Y279C/+ hearts revealed an enlarged and thickening heart, as compared to SHP2+/+ litter-
mate controls (Fig 2A). In response to treatment with ARQ 092 for 4 weeks, however, NSML
hearts showed a normalized morphology that was similar to that of SHP2+/+ hearts. Indeed,
overall heart weight in NSML hearts was normalized to weights similar to those in SHP2+/+
Fig 1. ARQ 092—Treated SHP2Y279C/+ hearts have normalized AKT/mTOR signaling. Mouse heart lysates were generated from wild-
type (SHP2+/+) and NSML (SHP2Y279C/+) littermates subjected to either vehicle or ARQ 092 treatment (100mg/kg/day orally) for 4 weeks,
starting at 12 weeks of age. The heart lysates were immunoblotted with anti—phospho-AKT, anti—phospho-S6RP and anti-phospho-
PRAS40, as indicated, followed by anti-AKT, anti-S6RP, and anti-PRAS40, respectively, to control for loading. Parallel experimental
samples were blotted with anti-SHP2 or anti-GAPDH to determine expression levels of these proteins. Quantification of data (n = 3–7 mice/
group) is shown to the right of each representative Western blot. Data represent mean ± SEM; *P < 0.05, 2-way ANOVA on ranked data, with
Bonferroni post hoc test when ANOVA was significant.
https://doi.org/10.1371/journal.pone.0178905.g001
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hearts (Fig 2A and 2B); however, heart weight to body weight and heart weight to tibia length
ratios did not reach significance in our experiments, likely due to the dip in body weight in the
first 2 weeks in response to the ARQ 092 treatment and the disproportionate effects of bone
structure to body length ratios in NSML mice, respectively, that might confound those ratio
measurements [S1 Fig and [12]]. Assessment of individual cardiomyocytes in H&E and reticu-
lin-stained heart sections from 16-week-old SHP2Y279C/+ mice indicated that NSML hearts
had enlarged individual cardiomyocytes, with increased overall cell surface area, that was nor-
malized in response to the AKT inhibitor treatment of these mice (Fig 2A and 2C).
ARQ 092 treatment improves cardiac function in NSML mice
To determine the effects of ARQ 092 on cardiac function, we conducted echocardiographic
analysis of SHP2+/+ and SHP2Y279C/+ littermates, either in the presence of orally administered
Fig 2. Treatment with ARQ 092 reduces cardiac hypertrophy and normalizes heart size in NSML. 16 week-old
SHP2 wild-type (SHP2+/+) and NSML (SHP2Y279C/+) littermates were treated with either vehicle or ARQ 092 AKT inhibitor
(of 100mg/kg/day orally) for 4 weeks, beginning at 12 weeks of age. (A). Representative transverse cross-section of
whole hearts (scale bar 1mm) and H&E- and Reticulin-stained sections (scale bar 50 microns); enlarged inset images
represent the indicated areas (scale bar 50 microns). Total heart weight (B) and cardiomyocyte cell size (C), as measured
from reticulin-stained heart cross-sections. *P < 0.05, where P values were derived from 2-way ANOVA on ranked data,
with Bonferroni post hoc test when ANOVA was significant; n = 3–7 mice/group.
https://doi.org/10.1371/journal.pone.0178905.g002
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vehicle or ARQ 092 (100mg/kg/day), at 12, 14, and 16 weeks of age (Table 1, S2 Fig). By 12
weeks of age, as previously reported [11], SHP2Y279C/+ mice showed significant left ventricular
hypertrophy, as indicated by decreased chamber dimension and increased posterior wall thick-
ness compared with those of littermate controls; hypertrophy in these mice continued to prog-
ress over the 4 week time period (Table 1, S2 Fig). Treatment of the SHP2Y279C/+ mice with
ARQ 092 normalized the HCM phenotype as early as 2 weeks following treatment, with levels
comparable to those in SHP2+/+ at this time point (Table 1, S2 Fig). Interestingly, we also
observed an increased fractional shortening, consistent with hypertrophy and increased con-
tractility, in vehicle-treated NSML hearts; this was not apparent in ARQ 092-treated mice
(Table 1), suggesting cardiac functional improvement. No functional changes or differences
were observed in hearts of SHP2+/+ mice, whether treated with vehicle or ARQ 092 (Table 1,
and S2 Fig).
Importantly, after 4 weeks of drug treatment, specific effects of the drug were observed
in the cardiac functional parameters (Fig 3, S3 Fig). Chamber dimension (LVIDd) was
increased (Fig 3A) and posterior wall thickness (LVPWd) was decreased (Fig 3B) in hearts
from SHP2Y279C/+ mice treated with the drug, as compared to hearts from SHP2Y279C/+ vehi-
cle-treated mice. Intraventricular septal dimension (IVSd), stroke volume (SV), and end-dia-
stolic volume (EDV) from SHP2Y279C/+ drug-treated mice were also normalized in response to
ARQ 092 treatment (Fig 3C, 3D and 3E), as compared to vehicle-treated controls. Interest-
ingly, we observed an increase in fractional shortening (FS%) over time in the SHP2Y279C/+
mice, a compensatory effect that usually occurs in response to a pathological stimulus; this
effect was not apparent in the SHP2Y279C/+ mice treated with the ARQ 092 drug (Fig 3F), sug-
gesting functional improvement upon treatment with ARQ 092.
Table 1. Anatomic and functional parameters, as assessed by echocardiography, in WT and NSML mice starting at 12 weeks of age and treated
for the indicated length of time with vehicle or ARQ 092.
Wildtype SHP2 Y279C/+
Baseline Vehicle ARQ092 Baseline Vehicle ARQ092
Age (weeks) 12 14 16 14 16 12 14 16 14 16
Tx (weeks) 0 2 4 2 4 0 2 4 2 4
IVSd (mm) 1.09±0.04 1.01±0.04 1.10±0.06 1.18±0.06 1.10±0.06 1.19±0.05 1.20±0.06 1.38±0.06 1.03±0.03 1.19±0.10
IVSs (mm) 1.82±0.04 1.78±0.04 1.76±0.08 1.83±0.05 1.74±0.04 2.09±0.22 1.92±0.04 2.24±0.25 1.90±0.36 1.94±0.04
LVIDd (mm) 1.91±0.06 1.99±0.15 1.94±0.14 1.83±0.09 1.88±0.11 1.61±0.07* 1.75±0.06 1.69±0.05^ 2.27±0.10 2.07±0.10#
LVIDs (mm) 0.41±0.03 0.42±0.04 0.43±0.08 0.41±0.03 0.43±0.05 0.27±0.02 0.27±0.04 0.33±0.01 0.37±0.07 0.36±0.06
LVPWd (mm) 1.07±0.03 1.11±0.08 1.30±0.12 1.04±0.07 1.24±0.14 1.32±0.04* 1.32±0.12 1.48±0.06^ 1.01±0.09 1.23±0.22#
LVPWs (mm) 2.03±0.07 2.19±0.05 2.35±0.16 2.25±0.07 2.22±0.12 2.08±0.06 2.09±0.16 2.33±0.09 2.21±0.03 2.31±0.16
EDV (ml) 0.02±0.00 0.02±0.00 0.02±0.04 0.02±0.00 0.02±0.00 0.01±0.00 0.01±0.04 0.01±0.00^ 0.03±0.00 0.02±0.00#
EF (%) 87.83±0.23 89.25±1.79 89.22±1.72 87.64±0.20 87.39±0.50 92.23±1.56 93.06±4.37 96.88±2.22 88.19±.29 88.21±0.35
SV (ml) 0.02±0.00 0.02±0.00 0.02±0.00 0.02±0.00 0.02±0.00 0.01±0.00 0.01±.00 0.01±0.00^ 0.03±.00 0.02±.00#
FS (%) 70.47±1.22 70.95±2.32 71.11±2.56 68.79±0.84 68.14±2.53 77.76±1.96* 85.04±1.68 80.39±0.78^ 74.88±2.25 73.31±2.36
Heart rate 670±10 673±30 680±13 672±15 673±31 668±10 682±28 714±18 673±13 697±25
Note: Baseline measurements are at 12 weeks of age. Mice were treated with either vehicle or ARQ 092 and then measured for cardiac function at 2 and 4
weeks of treatment. Mice were all sacrificed at 16 weeks of age. Data represent mean ± SEM. *, p<0.05, SHP2+/+ baseline vs. SHP2Y279C/+ baseline; ^,
p<0.05, SHP2+/+ vehicle vs. SHP2Y279C/+ vehicle at 4 weeks; #, p<0.05, SHP2Y279C/+ vehicle at 4 weeks vs. SHP2Y279C/+ ARQ 092 at 4 weeks, where P
values were derived from 2-way ANOVA on ranked data, with Bonferroni post hoc test when ANOVA was significant; n = 3–7 mice/group. IVSd,
intraventricular septal diameter in diastole; IVSs, intraventricular septal diameter in systole; LVIDd, left ventricular chamber dimension in diastole; LVIDd,
left ventricular chamber dimension in systole; LVPWd, left ventricular posterior wall thickness in diastole; LVPWs, left ventricular posterior wall thickness in
systole; EDV, end diastolic volume; EF%, ejection fraction; SV, stroke volume; FS%, fractional shortening.
https://doi.org/10.1371/journal.pone.0178905.t001
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Discussion
SHP2Y279C/+ mice have short stature, craniofacial dysmorphia, skeletal abnormalities, as well
as pathological cardiac hypertrophy [11,12]. Biochemically, SHP2Y279C/+ mutant hearts have
elevated AKT/mTOR activity, and we have previously shown that inhibiting mTOR with intra-
peritoneally-injected rapamycin could completely normalize and reverse the NSML cardiac
defects, both in vitro and in vivo [11]. Here, we sought to determine whether inhibition
upstream of mTOR, at the level of AKT, could similarly ameliorate the effects of hypertrophy
in SHP2Y279C/+ mice. Moreover, as the ArQule allosteric AKT inhibitor, ARQ 092, is orally
bioavailable, potent and selective, use of this inhibitor may be more readily tolerated and
accepted by patients for treatment of NSML-associated cardiac hypertrophy.
Our results indicate that inhibition of AKT by ARQ 092 reduces hypertrophy in SHP2Y279C/+
mice, as early as 2 weeks following treatment, with normalized effects on the posterior wall
thickness and chamber dimensions of treated SHP2Y279C/+ mouse hearts. Moreover, treatment
with the ARQ 092 compound reduced the elevated fractional shortening (FS%) seen in the
SHP2Y279C/+ vehicle-treated mice, an effect often associated with pathological compensatory
Fig 3. SHP2Y279C/+ hearts treated with ARQ 092 have improved cardiac function. Echocardiography was used to analyze the cardiac function in
SHP2+/+ and SHP2Y279C/+ mice, either vehicle or ARQ 092 treated for 4 weeks, starting at 12 weeks of age. (A) LVIDd, (B) LVPWd, (C) SV (D) IVSs,
(E) IVSd, and (F) FS% parameters were measured Data represent mean ± SEM. *P < 0.05, where P values were derived from from 2-way ANOVA on
ranked data, with Bonferroni post hoc test when ANOVA was significant; n = 3–7 mice/group. LVIDd, left ventricular chamber dimension in diastole;
LVPWd, left ventricular posterior wall thickness in diastole; SV, stroke volume; IVSs, intraventricular septal diameter in systole; IVSd, intraventricular
septal diameter in diastole; FS%, fractional shortening.
https://doi.org/10.1371/journal.pone.0178905.g003
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hypertrophy, therefore suggesting that the inhibitor prevents the onset of this pathological
event.
Importantly, we observed an overall decrease in overall heart weight in treated SHP2Y279C/+
mice; however, we did not see significant improvement in HW/BW ratios. In addition, we
measured HW/TL ratios. We have previously found that bone structure/body length ratios are
disproportionate in NSML mice, despite significant decreases in body weight [12]. Hereto, we
found that tibia lengths in SHP2Y279C/+ mice are similar to SHP2+/+. As such, while we see a
trending improvement in HW/TL ratios, we don’t reach significance. While we did not
observe any other non-cardiac specific effects of the inhibitor in treated mice, we found that
mice treated with ARQ 092 had reduced body weight, at least in the first two weeks of treat-
ment, possibly due to administration by oral gavage, and/or to the direct use of the AKT inhib-
itor itself. Considering the significant involvement of AKT in several important biological
processes, including adipogenesis and metabolic function, it is possible that AKT inhibition
does indeed affect weight gain [17]. This effect may also contribute to the lack of significance
in the physiological parameters for HW/BW ratios. Alternatively, it is possible that the 4 week
time period in which this study was conducted is not sufficient to see overall improvement in
HW/BW or HW/TL measures.
Additional evidence for positive effects of AKT/mTOR inhibition has been demonstrated.
Previous pharmacological studies have shown that treatment of cardiomyocytes with an AKT
inhibitor could prevent the hypertrophic response evoked by stimulation with various agonists
[18–21]. Inhibition of AKT/mTOR signaling also attenuates or reverses pressure overload-
associated cardiac hypertrophy [19,22,23], supporting our findings that there is a potential reg-
ulatory role for AKT/mTOR in pathological HCM in NSML [11,12].
In summary, our data support the conclusion that excessive AKT/mTOR leads to the devel-
opment and maintenance of HCM in NSML, and that ARQ 092, a potent, selective, and orally
bioavailable AKT inhibitor, can reverse hypertrophic cardiomyopathy in SHP2Y279C/+ mice.
Although these findings hold promise for the treatment of hypertrophy in NSML, additional
experiments, including use of an enlarged sample size, an optimization of dose and treatment
duration, a measure of possible adverse effects, inhibitor effects on mortality or hemodynam-
ics, and/or an assessment of the impact of inhibition of AKT itself, will be required to fully
assess the clinical value of this inhibitor on this, and perhaps other, more common, congenital
hypertrophy disorders that affect the AKT/mTOR signaling pathway.
Materials and methods
Histology
Hearts for morphometry and histochemistry were flushed with PBS, perfusion fixed in forma-
lin or Bouin’s reagent, and paraffin embedded. Sections (5 μm) were stained with H&E, Mas-
son-Trichrome, or reticulin at the Rodent Histopathology Core at Harvard Medical School.
Crosssectional length, width, and area of cardiomyocytes with centrally located nuclei (to
ensure the same plane of sectioning) were measured using ImageJ 1.41 software (developed by
Wayne Rasband; http://rsbweb.nih.gov/ij/). Three individual samples were analyzed for each
genotype, with 200–500 cells measured in each.
Echocardiography
Transthoracic echocardiography was conducted on nonanesthetized animals as described pre-
viously [11,12], with a 13-MHz probe (Vivid 7, GE Medical Systems) or VisualSonics Vevo
770 high-frequency ultrasound rodent imaging system. GE Medical Systems or VisualSonics
Vevo 770 software was used for data acquisition and subsequent analysis. Hearts were imaged
In vivo efficacy of the AKT inhibitor ARQ 092 in NSML-associated HCM
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in the 2-dimensional parasternal short-axis view, and an M-mode echocardiogram of the mid-
ventricular region was recorded at the level of the papillary muscles. Calculations of cardiac
anatomic and functional parameters were carried out as described previously [11,12].
Biochemical analyses
Whole hearts from SHP2+/+ or SHP2Y279C/+ mice were dissected, perfused in PBS, and imme-
diately frozen in liquid N2. Whole-cell lysates were prepared by homogenizing the tissue in
radioimmunoprecipitation (RIPA) buffer (25 mmol/l Tris-HCl [pH 7.4], 150 mmol/l NaCl,
0.1% SDS, 1% NP-40, 0.5% sodium deoxycholate, 5 mmol/l EDTA, 1 mmol/l NaF, 1 mmol/l
sodium orthovanadate, and a protease cocktail) at 4˚C, followed by clarification at 14,000 g.
Proteins were resolved by SDS-PAGE and transferred to PVDF membranes. Immunoblots
were subsequently performed, following the manufacturer’s directions, with anti-AKT and
anti-SHP2 antibodies (Santa Cruz Biotechnology Inc.); anti-phospho-S6RP, anti-phospho-
PRAS40, anti-phospho-Akt473, anti-S6RP, and anti-PRAS40 antibodies (Cell Signaling Tech-
nology); and anti-GAPDH (Millipore). Bands were visualized with enhanced chemilumines-
cence and quantified by densitometry (developed by Wayne Rasband; ImageJ 1.41 software,
http://rsbweb.nih.gov/ij/).
Mice
SHP2Y279C/+ mice were described previously [11,12], and are now available from Jackson Lab-
oratory as Stock No. 026759. Only male progeny were used for the experiments herein and
all mice were maintained on outbred C57BL6/J backgrounds, backcrossed for more than 10
generations. All animal studies were approved by the Beth Israel Deaconess Medical Center
IACUC Committee and performed in accordance with IACUC standards.
In vivo AKT inhibitor studies
ARQ 092(ArQule, Inc) was dissolved in 0.01M phosphoric acid (vehicle) at a concentration of
20 mg/ml and filter sterilized. Either vehicle or ARQ 092 (100 mg/kg body weight) was then
daily administered by oral gavage for 4 weeks. Administration began at 12 weeks of age (after
established hypertrophy was indicated), and continued for 4 weeks, until the mice reached 16
weeks of age. As controls, SHP2+/+ and SHP2Y279C/+ mice were treated with vehicle alone.
Statistics
All data are expressed as mean ± SEM. Statistical significance was determined using 2-tailed
Student’s t test and 2-way ANOVA on ranked data, with Bonferroni post hoc test when
ANOVA was significant; n = 3–7 mice/group. For all studies, values of P < 0.05 were consid-
ered statistically significant.
Supporting information
S1 Fig. Treatment with ARQ 092 reduces cardiac hypertrophy and normalizes heart size in
NSML. (A). Heart weight to body weight ratio; (B) Heart weight to tibia length ratio; (C) Body
weight; and (D) Tibia length of 16 week-old SHP2+/+ and SHP2Y279/+ littermates, either in the
presence of vehicle or ARQ 092 AKT inhibitor for 4 weeks. Data represent mean ± SEM.
P < 0.05, where P values were derived from 2-way ANOVA on ranked data, with Bonferroni
post hoc test when ANOVA was significant; n = 3–7 mice/group.
(TIF)
In vivo efficacy of the AKT inhibitor ARQ 092 in NSML-associated HCM
PLOS ONE | https://doi.org/10.1371/journal.pone.0178905 June 5, 2017 8 / 10
S2 Fig. Representative echocardiography for ARQ 092 treated NSML mice. Representative
echocardiographs of 16 week-old SHP2+/+ and SHP2Y279C/+ mice, at baseline, at 2 weeks, and
at 4 weeks of treatment with either vehicle or ARQ 092. Baseline measurements began at 12
weeks of age and continued for 4 weeks, until 16 weeks of age.
(TIF)
S3 Fig. SHP2Y279C/+ hearts treated with ARQ 092 have improved cardiac function. (dot plot
analysis). Echocardiography from individual mice was used to analyze the cardiac function in
SHP2+/+ and SHP2Y279C/+ mice, either vehicle or ARQ 092 treated for 4 weeks, starting at 12
weeks of age. (A) LVIDd, (B) LVPWd, (C) SV (D) IVSs, (E) IVSd, and (F) FS% parameters
were measured Data represent mean ± SEM. P< 0.05, where P values were derived from
from 2-way ANOVA on ranked data, with Bonferroni post hoc test when ANOVA was signifi-
cant; n = 3–7 mice/group. LVIDd, left ventricular chamber dimension in diastole; LVPWd,
left ventricular posterior wall thickness in diastole; SV, stroke volume; IVSs, intraventricular
septal diameter in systole; IVSd, intraventricular septal diameter in diastole; FS%, fractional
shortening.
(TIF)
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